Feasibility of rapid point-of-care diagnostic test for TB
Start a new DMP in Loading
There were an estimated 8.8 million new cases of TB in 2010 and an estimated 1.4 million deaths, making this disease one of the world's biggest infectious killers. It is estimated that 1/3 of the global population is infected with latent disease. Disease transmission occurs primarily via droplets from coughing and sneezing. Early diagnosis and treatment of infective cases is key to preventing the spread of TB. ProteinLogic have established a unique protein ‘signature’ which can discriminate infectious cases from latent carriers of the disease. OJ-Bio have developed a rapid diagnostic sensor platform suitable for point-of-care tests. This project aims to show feasibility of quanitification of ProteinLogic TB biomarkers in serum using the OJ-Bio platform. It will enable ProteinLogic and OJ-Bio to collaborate to further develop their technologies together in order to develop a rapid point-of-care blood test for TB.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://beta.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=ukri________::9ddc92f47bc4a02dda4aa6d06933a9fb&type=result"></script>');
-->
</script>